In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

The sell-off started last night and continued in after-hours trading after the New York-based biopharma company revealed that ...

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's gene therapy for the rare ...

Great Place to Work, Built Ins: Top Biotech Companies 2024, Forbes Best Places to Work in Life Sciences are joining our LEAP ...

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a ...

Barcelona-based Grifols has seen its stock value plummet since January when short seller Gotham City Research accused the company of manipulating debt and earnings reporting by consolidating profit ...

Advanz won a temporary reprieve in September after the General Court of the European Union ordered a suspension of the EC's ...

Trump has nominated Dr Jay Bhattacharya, a 56-year-old physician and health economist at Stanford University School of ...

Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory ...

Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare Disorders ...

“It’s a really exciting time, not just for NWEH, but also for the future of clinical trials in the UK. If successful, this ...